Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

This RCT (n=391) found no clinically meaningful change in Trial Outcome Index score at 24 months within or between olaparib and placebo groups but did report a significant increase of 12.17 months ([95% CI 9.07–15.11] p<0·0001) for mean quality-adjusted progression-free survival.

Source:

The Lancet Oncology